SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biolase, Inc – ‘10-K’ for 12/31/13 – ‘EX-31’

On:  Monday, 3/17/14, at 4:22pm ET   ·   For:  12/31/13   ·   Accession #:  1564590-14-856   ·   File #:  0-19627

Previous ‘10-K’:  ‘10-K’ on 3/15/13 for 12/31/12   ·   Next:  ‘10-K/A’ on 4/30/14 for 12/31/13   ·   Latest:  ‘10-K’ on 3/21/24 for 12/31/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/17/14  Biolase, Inc                      10-K       12/31/13   76:14M                                    ActiveDisclosure/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.28M 
 2: EX-4        Ex-4.4                                              HTML     29K 
 3: EX-10       Ex-10.42                                            HTML     61K 
 4: EX-21       Ex-21.1                                             HTML     21K 
 5: EX-23       Ex-23.1                                             HTML     23K 
 6: EX-31       Ex-31.1                                             HTML     29K 
 7: EX-31       Ex-31.2                                             HTML     29K 
 8: EX-32       Ex-32.1                                             HTML     25K 
 9: EX-32       Ex-32.2                                             HTML     25K 
53: R1          Document and Entity Information                     HTML     53K 
43: R2          Consolidated Balance Sheets                         HTML    144K 
51: R3          Consolidated Balance Sheets (Parenthetical)         HTML     51K 
55: R4          Consolidated Statements Of Operations And           HTML    107K 
                Comprehensive Loss                                               
71: R5          Consolidated Statements Of Shareholders' Equity     HTML    101K 
                (Deficit)                                                        
45: R6          Consolidated Statements Of Cash Flows               HTML    176K 
50: R7          Basis of Presentation                               HTML     55K 
39: R8          Summary of Significant Accounting Policies          HTML    152K 
30: R9          Supplementary Balance Sheet Information             HTML    122K 
72: R10         Intangible Assets and Goodwill                      HTML     92K 
57: R11         Lines of Credit and Other Borrowings                HTML     44K 
56: R12         Income Taxes                                        HTML    190K 
62: R13         Commitments and Contingencies                       HTML     56K 
63: R14         Stockholders' Equity                                HTML    274K 
61: R15         Segment Information                                 HTML     49K 
64: R16         Concentrations                                      HTML     26K 
52: R17         Subsequent Events                                   HTML     38K 
54: R18         Schedule II-Consolidated Valuation and Qualifying   HTML     88K 
                Accounts and Reserves                                            
60: R19         Accounting Policies (Policies)                      HTML    306K 
76: R20         Summary of Significant Accounting Policies          HTML    109K 
                (Tables)                                                         
67: R21         Supplementary Balance Sheet Information (Tables)    HTML    129K 
47: R22         Intangible Assets and Goodwill (Tables)             HTML     83K 
58: R23         Income Taxes (Tables)                               HTML    183K 
49: R24         Commitments and Contingencies (Tables)              HTML     31K 
24: R25         Stockholders' Equity (Tables)                       HTML    229K 
68: R26         Segment Information (Tables)                        HTML     41K 
73: R27         Basis of Presentation - Additional Information      HTML     52K 
                (Detail)                                                         
34: R28         Estimated Useful Lives of Property, Plant and       HTML     28K 
                Equipment (Detail)                                               
33: R29         Changes in Initial Product Warranty Accrual and     HTML     41K 
                Expenses Under Initial and Extended Warranties                   
                (Detail)                                                         
37: R30         Classification of Compensation Expense Associated   HTML     32K 
                with Share-Based Payments (Detail)                               
38: R31         Assumptions Used in Estimating Fair Value of Stock  HTML     35K 
                Options Granted (Detail)                                         
40: R32         Summary of Significant Accounting Policies -        HTML     57K 
                Additional Information (Detail)                                  
22: R33         Components of Accounts Receivable, Net of           HTML     31K 
                Allowance (Detail)                                               
65: R34         Components of Inventory (Detail)                    HTML     34K 
46: R35         Summary of Property, Plant, and Equipment (Detail)  HTML     45K 
48: R36         Components of Accrued Liabilities (Detail)          HTML     51K 
27: R37         Summary of Deferred Revenue (Detail)                HTML     40K 
75: R38         Supplementary Balance Sheet Information -           HTML     48K 
                Additional Information (Detail)                                  
16: R39         Intangible Assets and Related Accumulated           HTML     56K 
                Amortization (Detail)                                            
41: R40         Intangible Assets and Goodwill - Additional         HTML     44K 
                Information (Detail)                                             
70: R41         Lines of Credit and Other Borrowings - Additional   HTML    137K 
                Information (Detail)                                             
26: R42         Summary of Income Tax Current and Deferred          HTML     69K 
                Provision (Benefit) (Detail)                                     
32: R43         Federal Income Tax Provision Compared With          HTML     63K 
                Statutory Rates (Detail)                                         
36: R44         Summary of Net Deferred Tax Assets and Net          HTML     87K 
                Deferred Tax Liabilities (Detail)                                
44: R45         Summary of Unrecognized Tax Benefits (Detail)       HTML     31K 
21: R46         Income Taxes - Additional Information (Detail)      HTML     58K 
29: R47         Commitments and Contingencies - Additional          HTML     41K 
                Information (Detail)                                             
18: R48         Future Minimum Rental Commitments Under Operating   HTML     45K 
                Lease Agreements (Detail)                                        
69: R49         Summary of Option Activity (Detail)                 HTML     81K 
25: R50         Options Outstanding and Exercisable (Detail)        HTML     70K 
66: R51         Cash Proceeds Along with Fair Value Disclosures     HTML     41K 
                Related to Grants Exercises and Vesting Options                  
                (Detail)                                                         
28: R52         Stockholders' Equity - Additional Information       HTML    251K 
                (Detail)                                                         
42: R53         Summary of Net Revenue by Geographic Location       HTML     27K 
                (Detail)                                                         
17: R54         Segment Information - Additional Information        HTML     32K 
                (Detail)                                                         
20: R55         Concentrations - Additional Information (Detail)    HTML     36K 
35: R56         Subsequent Events - Additional Information          HTML     67K 
                (Detail)                                                         
23: R57         Consolidated Valuation and Qualifying Accounts and  HTML     36K 
                Reserves (Detail)                                                
74: XML         IDEA XML File -- Filing Summary                      XML    111K 
19: EXCEL       IDEA Workbook of Financial Reports                  XLSX    190K 
31: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   2.05M 
10: EX-101.INS  XBRL Instance -- biol-20131231                       XML   2.69M 
12: EX-101.CAL  XBRL Calculations -- biol-20131231_cal               XML    200K 
13: EX-101.DEF  XBRL Definitions -- biol-20131231_def                XML   1.08M 
14: EX-101.LAB  XBRL Labels -- biol-20131231_lab                     XML   1.53M 
15: EX-101.PRE  XBRL Presentations -- biol-20131231_pre              XML   1.21M 
11: EX-101.SCH  XBRL Schema -- biol-20131231                         XSD    220K 
59: ZIP         XBRL Zipped Folder -- 0001564590-14-000856-xbrl      Zip    215K 


‘EX-31’   —   Ex-31.1


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



Exhibit 31.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Federico Pignatelli, certify that:

1. I have reviewed this Annual Report on Form 10-K of BIOLASE, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s fourth fiscal quarter ended December 31, 2013 that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of Registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize, and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

Date: March 17, 2014

 

 

By:

 

/s/    FEDERICO PIGNATELLI

 

 

Federico Pignatelli

 

 

Chief Executive Officer

 

 

(Principal Executive Officer)

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/17/148-K/A,  DEFA14A
For Period end:12/31/1310-K/A,  SD
 List all Filings 
Top
Filing Submission 0001564590-14-000856   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 12:09:58.1pm ET